Monte Rosa Therapeutics, Inc. (GLUE) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $9.00K; Additional Paid in Capital, Common StockUSD $1.06B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-5.17M.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $8.00K; Additional Paid in Capital, Common StockUSD $1.05B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-4.75M.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $7.00K; Additional Paid in Capital, Common StockUSD $714.09M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-3.83M.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $6.00K; Additional Paid in Capital, Common StockUSD $680.16M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-3.25M.
Monte Rosa Therapeutics, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $9.00K | $1.06B | $-5.17M | $-565.11M | $487.28M | 3 month · $5.97M |
| 2026-03-31 | $0.00 | $8.00K | $1.05B | $-4.75M | $-521.72M | $521.92M | 3 month · $5.95M |
| 2025-12-31 | $0.00 | $7.00K | $714.09M | $-3.83M | $-477.21M | $233.06M | 12 month · $18.86M |
| 2025-09-30 | $0.00 | $6.00K | $680.16M | $-3.25M | $-431.08M | $245.84M | 3 month · $4.36M |
| 2025-06-30 | $0.00 | $6.00K | $675.45M | $-3.37M | $-404.00M | $268.08M | 3 month · $4.89M |
| 2025-03-31 | $0.00 | $6.00K | $670.19M | $-3.33M | $-391.70M | $275.16M | 3 month · $5.30M |
| 2024-12-31 | $0.00 | $6.00K | $664.87M | $-3.36M | $-438.59M | $222.94M | 12 month · $18.13M |
| 2024-09-30 | $0.00 | $6.00K | $659.80M | $-2.32M | $-452.02M | $205.46M | 3 month · $4.28M |
| 2024-06-30 | $0.00 | $6.00K | $655.50M | $-2.67M | $-428.17M | $224.67M | 3 month · $4.50M |
| 2024-03-31 | $0.00 | $5.00K | $553.06M | $-2.69M | $-397.86M | $152.52M | 3 month · $4.87M |
| 2023-12-31 | $0.00 | $5.00K | $547.86M | $-2.72M | $-365.89M | $179.25M | 12 month · $16.67M |
| 2023-09-30 | $0.00 | $5.00K | $518.61M | $-1.46M | $-332.64M | $184.52M | 3 month · $4.47M |
| 2023-06-30 | $0.00 | $5.00K | $513.04M | $-1.64M | $-297.75M | $213.65M | 3 month · $4.15M |
| 2023-03-31 | $0.00 | $5.00K | $507.69M | $-1.39M | $-262.57M | $243.73M | 3 month · $3.97M |
| 2022-12-31 | $0.00 | $5.00K | $503.70M | $-1.75M | $-230.54M | $271.41M | 12 month · $11.66M |
| 2022-09-30 | (m) | $5.00K | $493.44M | $-2.60M | $-199.75M | $291.09M | 3 month · $3.21M |
| 2022-06-30 | (m) | $5.00K | $476.94M | $-2.46M | $-172.44M | $302.05M | 3 month · $2.87M |
| 2022-03-31 | (m) | $5.00K | $473.97M | $-2.13M | $-145.97M | $325.88M | 3 month · $2.25M |
| 2021-12-31 | $0.00 | $5.00K | $471.57M | $-2.02M | $-122.03M | $347.51M | 12 month · $5.20M |
| 2021-09-30 | (m) | $5.00K | $469.85M | $-1.95M | $-98.59M | $369.31M | 3 month · $2.07M |
| 2021-06-30 | (m) | $4.00K | $436.85M | $-1.42M | $-78.76M | $356.68M | 3 month · $1.02M |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | $-60.62M | 3 month · $252.00K |
| 2020-12-31 | (m) | $1.00K | $404.00K | $-1.06M | $-48.08M | $-48.73M | 12 month · $354.00K |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | $-28.22M | 3 month · $45.00K |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | $-21.71M | 3 month · $97.00K |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | $-16.44M | 3 month · $11.00K |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | $-12.15M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |